SCHEMBL4775679

SCHEMBL4775679

CON(C)S(=O)(=O)c1ccc(S(=O)(=O)C2CCNCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.40
MMP13 P45452 2/20 0.38
HTR2C P28335 3/20 0.36
HTR2B P41595 2/20 0.36
MMP1 P03956 1/20 0.36
MMP8 P22894 1/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
CNR2 P34972 1/20 0.35
HTR2A P28223 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NAMPT P43490 3/20 0.35
NMT1 P30419 2/20 0.35
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CYP3A4 P08684 1/20 0.33
GABRA1 P14867 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4770290 0.84 HTR2C (0.50) ALDH1A1HTR2CHTR2BSLC6A2SLC6A4
SCHEMBL4775699 0.82 GBA1 (0.46) ALDH1A1GAAKDM4EMAPTHTR2C
SCHEMBL10795088 0.78 MMP13 (0.59) ALDH1A1GAAMAPTMMP13MMP1
SCHEMBL4771017 0.78 HTT (0.53) ALDH1A1GAAMAPTL3MBTL1LMNA
Hydrochloric Acid SCHEMBL4773848 0.77 MMP13 (0.57) ALDH1A1MAPTMMP13HTR2CMMP1
SCHEMBL12017803 0.76 HTR6 (0.46) ALDH1A1GAACNR2NAMPTLMNA
Hydrochloric Acid SCHEMBL4772957 0.74 PTGS2 (0.41) MMP13CNR2NAMPTLMNACYP3A4
SCHEMBL4770310 0.73 HTR2A (0.39) ALDH1A1GAAKDM4EMAPTHTR2C
SCHEMBL18318428 0.73 NAMPT (0.42) MMP13HTR2CMMP1MMP8CNR2
SCHEMBL5212828 0.73 CYP11B1 (0.49) HTR2CHTR2BHTR2ANAMPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 ALDH1A1 3228/4885GAA 4215/4885KDM4E 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.